Clinical Trial

Determining Minimal Residual Disease Using ctDNA Deep Sequencing

Study acronym: CIT-SEQ
Recruiting
View on ClinicalTrials.gov →
Summary
Preoperative neoadjuvant chemotherapy is the standard treatment for locally advanced gastrointestinal tumours. However, not all patients respond to preoperative treatment. Early identification of progression during neoadjuvant chemotherapy or diagnosis of early disease relapse during adjuvant treatment is essential to modify the treatment strategy. The aim of this project is to validate ctDNA as a biomarker of molecular relapse/progression of disease.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-16.
Trial Details
NCT Number NCT07660627
Lead Sponsor Masaryk Memorial Cancer Institute
Conditions Esophageal Adenocarcinoma, Gastric Cancer, Pancreatic Cancer
Enrollment 34 participants
Start Date 2022-08-22
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-24